Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/lymphotoxin β-receptor pathway

Thrombosis and Haemostasis

Volumn 116, Issue 2, 2016, Pages 379-393

  Andrés Blasco, Irene ^a   Vinué, Angela ^a   Herrero Cervera, Andrea ^a   Martinez Hervás, Sergio ^a,b,c   Nuñez, Laura ^a   Piqueras, Laura ^a   Ascaso, Juan F ^a,b,c   Sanz, Maria Jesús ^a,b   Burks, Deborah Jane ^c,d   González Navarro, Herminia ^a,c  

^a Instituto Universitario IVI INCLIVA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Atherosclerosis; Hepatic lipase; Inflammation; Insulin resistance; Macrophage

Indexed keywords

APOLIPOPROTEIN E; CD69 ANTIGEN; HERPESVIRUS ENTRY MEDIATOR LIGAND; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIVER TRIACYLGLYCEROL LIPASE; LYMPHOTOXIN BETA RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, MOUSE; LIPC PROTEIN, MOUSE; LTBR PROTEIN, HUMAN; LTBR PROTEIN, MOUSE; MESSENGER RNA; TNFSF14 PROTEIN, HUMAN; TNFSF14 PROTEIN, MOUSE; TRIACYLGLYCEROL LIPASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; GENE EXPRESSION; GENETIC MANIPULATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; MACROPHAGE; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; APOLIPOPROTEIN E KNOCKOUT MOUSE; ATHEROGENIC DIET; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION MEDIATORS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIPASE; LYMPHOTOXIN BETA RECEPTOR; MALE; METABOLIC SYNDROME; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, KNOCKOUT, APOE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 84982734929     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-10-0773     Document Type: Article

References (51)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med 2007; 356: 213-215.
2. Neeli H, Gadi R, Rader DJ. Managing diabetic dyslipidaemia: beyond statin therapy. Curr Diab Rep 2009; 9: 11-17.
3. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidaemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
4. Todorova B, Kubaszek A, Pihlajamaki J, et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004; 89: 2019-2023.
5. Lopez-Rios L, Novoa FJ, Chirino R, et al. Interaction between cholesteryl ester transfer protein and hepatic lipase encoding genes and the risk of type 2 diabetes: results from the Telde study. PLoS One 2011; 6: e27208.
6. Zacharova J, Todorova BR, Chiasson JL, et al. The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. J Intern Med 2005; 257: 185-193.
7. Zhang C, Lopez-Ridaura R, Rimm EB, et al. Genetic variation in the hepatic lipase gene and the risk of coronary heart disease among US diabetic men: potential interaction with obesity. Diabetologia 2006; 49: 1552-1559.
8. Gonzalez-Navarro H, Nong Z, Amar MJ, et al. The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice. J Biol Chem 2004; 279: 45312-45321.
9. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, et al. Hepatic lipase, li-poprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1750-1754.
10. Brunzell JD, Zambon A, Deeb SS. The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Bio-chim Biophys Acta 2011; 1821: 365-372.
11. Teran-Garcia M, Santoro N, Rankinen T, et al. Hepatic lipase gene variant -514C>T is associated with lipoprotein and insulin sensitivity response to regular exercise: the HERITAGE Family Study. Diabetes 2005; 54: 2251-2255.
12. Carr MC, Brunzell JD. Abdominal obesity and dyslipidaemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidaemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-2607.
13. Bergeron N, Kotite L, Verges M, et al. Lamellar lipoproteins uniquely contribute to hyperlipidaemia in mice doubly deficient in apolipoprotein E and hepatic li-pase. Proc Natl Acad Sci USA 1998; 95: 15647-15652.
14. Norata GD, Raselli S, Grigore L, et al. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis 2009; 206: 556-562.
15. Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol 2015; 35: 258-264.
16. Andres V, Pello OM, Silvestre-Roig C. Macrophage proliferation and apoptosis in atherosclerosis. Curr Opin Lipidol 2012; 23: 429-438.
17. Dickson BC, Gotlieb AI. Towards understanding acute destabilization of vulnerable atherosclerotic plaques. Cardiovasc Pathol 2003; 12: 237-248.
18. Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ Res 2010; 106: 58-67.
19. Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332: 1284-1288.
20. Martinez-Hervas S, Vinue A, Nunez L, et al. Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis. Cardiovasc Res 2014; 103: 324-336.
21. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009; 30: 2838-2844.
22. Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol 2015; 35: 280-287.
23. Gonzalez-Navarro H, Nong Z, Freeman L, et al. Identification of mouse and human macrophages as a site of synthesis of hepatic lipase. J Lipid Res 2002; 43: 671-675.
24. Hime NJ, Black AS, Bulgrien JJ, et al. Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP. J Lipid Res 2008; 49: 2113-2123.
25. Nong Z, Gonzalez-Navarro H, Amar M, et al. Hepatic lipase expression in mac-rophages contributes to atherosclerosis in apoE-deficient and LCAT-transgenic mice. J Clin Invest 2003; 112: 367-378.
26. Escola-Gil JC, Chen X, Julve J, et al. Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant properties. Biochim Biophys Acta 2013; 1831: 691-697.
27. Klingenberg R, Gerdes N, Badeau RM, et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolaemia and atherosclerosis. J Clin Invest 2013; 123: 1323-1334.
28. Lo JC, Wang Y, Tumanov AV, et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007; 316: 285-288.
29. Gonzalez-Navarro HV-C, M. Pastor, M-F. Vinue, A. White, M. F. Burks, DA, V. Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolaemia in apolipoprotein E-null mice. Frontiers in Bioscience 2007; 12: 2291-2298.
30. Gonzalez-Navarro H, Vinue A, Vila-Caballer M, et al. Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced IRS2-dependent signaling. Arterioscler Thromb Vasc Biol 2008; 28: 2187-2194.
31. Gonzalez-Navarro H, Abu Nabah YN, Vinue A, et al. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol 2010; 55: 2258-2268.
32. Chellan B, Koroleva EP, Sontag TJ, et al. LIGHT/TNFSR14 can regulate hepatic lipase expression by hepatocytes independent of T cells and Kupffer cells. PLoS One 2013; 8: e54719.
33. Kozakova M, Natali A, Dekker J, et al. Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. Arterioscler Thromb Vasc Biol 2013; 33: 1409-1417.
34. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-1520.
35. Shaikh RB, Santee S, Granger SW, et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 2001; 167: 6330-6337.
36. Lewis GF, Murdoch S, Uffelman K, et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglita-zone. Diabetes 2004; 53: 2893-2900.
37. Ahmad T, Chasman DI, Buring JE, et al. Physical activity modifies the effect of LPL, LIPC, and CETP polymorphisms on HDL-C levels and the risk of myocardial infarction in women of European ancestry. Circ Cardiovasc Genet 2011; 4: 74-80.
38. Saisho Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocr Metab Immune Disord Drug Targets 2015; 15: 196-205.
39. Escudero P, Martinez de Maranon A, Collado A, et al. Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARalpha and RXR/PPARgamma interactions. Antioxid Redox Signal 2015; 22: 901-920.
40. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011; 14: 575-585.
41. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-355.
42. Doherty TA, Soroosh P, Khorram N, et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat Med 2011; 17: 596-603.
43. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholes-terolaemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
44. Pello OM, Silvestre C, De Pizzol M, et al. A glimpse on the phenomenon of mac-rophage polarization during atherosclerosis. Immunobiology 2011; 216: 1172-1176.
45. Scholz H, Sandberg W, Damas JK, et al. Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis. Circulation 2005; 112: 2121-2129.
46. Owens AW, Matulevicius S, Rohatgi A, et al. Circulating lymphotoxin beta receptor and atherosclerosis: observations from the Dallas Heart Study. Atherosclerosis 2010; 212: 601-606.
47. Grandoch M, Feldmann K, Gothert JR, et al. Deficiency in lymphotoxin beta receptor protects from atherosclerosis in apoE-deficient mice. Circ Res 2015; 116: e57-68.
48. Hu D, Mohanta SK, Yin C, et al. Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin beta Receptors. Immunity 2015; 42: 1100-1115.
49. Wei CY, Chou YH, Ho FM, et al. Signaling pathways of LIGHT induced macro-phage migration and vascular smooth muscle cell proliferation. J Cell Physiol 2006; 209: 735-743.
50. Gupta J, Nebreda AR. Roles of p38alpha mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer. Febs J 2015; 282: 1841-1857.
51. Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 2015; 12: 199-211.